What we cover
Retinal disease
Wet AMD, diabetic macular oedema, geographic atrophy, and inherited retinal dystrophy. Anti-VEGF biosimilars and the complement-targeted therapy class.
Glaucoma
Pressure-lowering pharmacology, drug-delivery implants, and the surgical-pharmacological interplay that defines real-world disease control.
Front-of-eye disease
Dry eye, allergic conjunctivitis, and the biologic and small-molecule pipeline targeting front-of-eye inflammation.
Imaging & access
OCT and OCT-A capacity, intravitreal-injection workflow, and the access bottlenecks that gate uptake of approved retinal therapy.
Latest signals
See all →Neurotrophic keratitis acquires recombinant nerve growth factor therapy
Cenegermin (recombinant nerve growth factor) maturity, follow-on programs, and structured corneal-care pathways are reshaping neurotrophic keratitis management.
Retinal vein occlusion therapy options widen past first-generation anti-VEGF
Faricimab and high-dose aflibercept extension, structured macular edema management, and emerging mechanism programs are reshaping retinal vein occlusion management.
Proliferative diabetic retinopathy therapy reshapes around anti-VEGF
Anti-VEGF first-line for proliferative diabetic retinopathy, panretinal photocoagulation as alternative or combination, and emerging mechanism programs are reshaping PDR management.
Snapshots
See all →Retinal vein occlusion therapy reference (2026)
Reference snapshot of RVO therapy across acute and ongoing macular edema management plus systemic care integration.
Allergic conjunctivitis therapy reference (2026)
Reference snapshot of allergic conjunctivitis therapy across mild seasonal, persistent, severe, and emerging tiers.
Presbyopia therapy reference (2026)
Reference snapshot of presbyopia management across optical, surgical, and pharmacological approaches.
Explained
See all →What is retinal vein occlusion?
Plain-language primer on retinal vein occlusion, why it is a vascular event, and what modern therapy can offer.
What is allergic conjunctivitis?
Plain-language primer on allergic conjunctivitis, the different types, and what the modern range of therapy can offer.
What is presbyopia?
Plain-language primer on presbyopia, why it affects nearly everyone with age, and what the modern range of options can offer.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.